Scientific Poster: “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”
The InMed-sponsored study demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates to reduce amyloid toxicity and tau protein expression while enhancing neuronal cell growth using in vitro models, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s.
Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function.
The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia.
Results were presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. A copy of the scientific poster can be found here.
